News Posts List
Considering a Clinical Trial? Phase II Clinical Study of Lenvatinib
06/17/2017
Eisai announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.
Conquer Cancer Foundation of ASCO Awards $5.65 Million to Support Cancer Research
06/06/2017
The Kidney Cancer Association announces another Young Investigator Award (YIA) made collaboratively with Conquer Cancer Foundation (ASCO). The Award is a research grant that supports promising investigators and encourages quality research in clinical oncology, providing funding during a physician’s pivotal career transition from a fellowship program to a faculty appointment.
Can regular aspirin use reduce your cancer risk?
06/03/2017
But when inflammation is chronic, lasting for months or even years due to injury or disease, it can become a perfect environment for many types of cancer cells to develop and thrive.
Better treatment for kidney cancer thanks to new mouse model
05/31/2017
Roughly 2-3 percent of all people suffering from cancer have kidney cancer. The most common form of this disease is called clear cell renal cell carcinoma (ccRCC). In roughly half of all patients with this disease, the tumor develops metastases and generally cannot be cured.
Four Tomatoes A Day May Reduce Kidney Cancer Risk
05/28/2017
Women who eat more tomatoes or other lycopene-containing fruits and vegetables may have a lower risk of developing kidney cancer, a study suggests.
Phase 2 Study Comparing CB-839 With Everolimus vs. Placebo With Everolimus
05/25/2017
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 2/3 Trial of Abexinostat In Renal Cell Carcinoma
05/23/2017
Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco ("UCSF") to conduct PAX Study, a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma ("RCC").
Doctors Excited By Results Of New Immunotherapy Cancer Treatment
05/05/2017
“We have never seen anything like this in most human solid tumors,” Allegheny Health Network Oncologist Dr. Gene Finley said.
FDA warns of 14 ‘fraudulent’ cancer cure companies
04/26/2017
The companies are taking advantage of frightened cancer patients and their loved ones, said consumer safety officer Nicole Kornspan.
Obesity fuelling rise in kidney cancer cases
04/25/2017
Being obese, with a body mass index ( BMI) of 30 or more, increases the risk of getting kidney cancer. It causes around 25% of cases in men and 22% in women.
News Feed